Key Documents

View All Documentation

53578-U

Ascentis^® Express 90 Å F5 (2.7 μm) HPLC Columns

Name: Ascentis<SUP>&#174;</SUP> Express 90 Å F5 (2.7 μm) HPLC Columns
Brand: SUPELCO

L × I.D. 10 cm × 3 mm, HPLC Column

Synonym(s):

Core-shell (SPP) Fused Core PFP HPLC column

Select a Size

Change View

About This Item

UNSPSC Code:

41115700

eCl@ss:

32110501

NACRES:

SB.52

L × i.d.:

10 cm × 3 mm

Particle size:

2.7 μm

Matrix active group:

PFP (pentafluorophenyl) phase

Pore size:

90 Å pore size

Matrix:

Fused-Core particle platform, superficially porous particle

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Ascentis^® Express F5, 2.7 μm HPLC Column, 2.7 μm particle size, L × I.D. 10 cm × 3 mm

material

stainless steel column

Quality Segment

100

agency

suitable for USP L43

product line

Ascentis^®

feature

endcapped

manufacturer/tradename

Ascentis^®

packaging

1 ea of

parameter

60 °C temp. range, 600 bar max. pressure (9000 psi)

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

L × I.D.

10 cm × 3 mm

surface area

135 m²/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform, superficially porous particle

matrix active group

PFP (pentafluorophenyl) phase

particle size

2.7 μm

pore size

90 Å pore size

operating pH

2-8

application(s)

food and beverages

separation technique

reversed phase

Description

General description

The pentafluorophenylpropyl stationary phase of Ascentis Express F5 provides a stable reversed phase packing with electron-deficient phenyl rings due to the presence of electronegative fluorines.In addition to forming pi-pi and mildly steric interactions, F5 phases also retain compounds by polar interactions. Ascentis Express F5 can be used for basic, acidic, or neutral compounds with alternate selectivity from C18.

Application

Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis^® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis^® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under Ascentis^® Express F5, 2.7 μm HPLC Column

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c